2016•BMJRequires access
Don’t dismiss pioglitazone on basis of uncertain risk
Alison Gallagher, Peter Winocour
Open publisher page 0 citations
Abstract
Tuccori and colleagues conclude that the use of pioglitazone is associated with increased risk of bladder cancer.1 However, in this study pioglitazone and non-pioglitazone users were not matched and, despite adjustment, pioglitazone users were older, had type 2 diabetes for longer, and had worse glycaemic control than non-pioglitazone users.2
It is worrying …